You're correct.
Clinicians in the real world are going to have patients who are clearly unresectable/have metastases, and then the rest for whom either surgery is an option or there's advanced local disease but it looks unresectable for technical reasons expertly outlined by you..
I suspect that, again in the real world, anything that makes the surgeons deal with a smaller tumour (even if it was clearly resectable) is going to be used.
BR might have definitions for the purposes of research, but the definitions for standard pre-op use of chemo and RT/oncosil will be more flexible.
And as far as research goes, the comparators need to be clear. You're comparing (pre-surgery) C+RT (either oncosil or other) against chemo alone. Then maybe oncosil vs other forms of RT.
But there are ethical issues in witholding treatment options in a disease with so few options as pancreatic cancer.
I personally think the acceptable RCTs will be smaller than people imagine.
- Forums
- ASX - By Stock
- OSL
- OSL Top Pick for FY21
OSL Top Pick for FY21, page-15
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OSL (ASX) to my watchlist
|
|||||
Last
1.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $45.40M |
Open | High | Low | Value | Volume |
1.2¢ | 1.2¢ | 1.1¢ | $65.61K | 5.632M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
14 | 6553895 | 1.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.2¢ | 1917493 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
14 | 6553895 | 0.011 |
15 | 11480500 | 0.010 |
25 | 14580403 | 0.009 |
6 | 6975000 | 0.008 |
12 | 4797857 | 0.007 |
Price($) | Vol. | No. |
---|---|---|
0.012 | 1917493 | 5 |
0.013 | 11116832 | 6 |
0.014 | 7811217 | 11 |
0.015 | 8500000 | 3 |
0.016 | 3766668 | 2 |
Last trade - 15.50pm 16/08/2024 (20 minute delay) ? |
Featured News
OSL (ASX) Chart |